OW 2025 4 - 7 November 2025

Improvements in Glycemic Parameters and Cardiovascular Risk Factors with Oral Semaglutide 25 mg

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Obesity

Congress oral presentation

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)

Are you a healthcare professional?